BioXcel Therapeutics (BTAI) Interest Expenses (2017 - 2026)

BioXcel Therapeutics' Interest Expenses history runs 10 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 5.13% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $16.7 million, a 94.77% increase from a year earlier, with the FY2025 full-year figure at $17.0 million, down 91.16% from the prior year.
• Interest Expenses eased to $4.2 million in Q1 2026 per BTAI's latest filing, from $4.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $118.4 million in Q4 2022 and bottomed at -$2.9 million in Q4 2024.
• The 5-year median for Interest Expenses is $4.2 million (2025), against an average of $17.3 million.
• Across the five-year window, Interest Expenses jumped 1972783.33% in 2022 and slumped 192.2% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $118.4 million in 2022, then tumbled by 97.36% to $3.1 million in 2023, then slumped by 192.2% to -$2.9 million in 2024, then surged by 252.43% to $4.4 million in 2025, then retreated by 4.5% to $4.2 million in 2026.
• Per Business Quant, the three latest BTAI Interest Expenses figures stand at $4.2 million (Q1 2026), $4.4 million (Q4 2025), and $3.9 million (Q3 2025).